Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALK-depot SQ mites is an allergen extract-based immunotherapy product developed by ALK-Abelló for the treatment of immune system diseases, particularly allergic conditions related to house dust mite sensitization. It is administered as a subcutaneous injection (SCIT) and functions as an immunomodulator, aiming to induce immune tolerance to house dust mite allergens. The drug has been studied in clinical trials for atopic dermatitis with proven IgE-mediated sensitization to house dust mites, showing improvements in skin and other organ manifestations associated with allergy[1][2][4]. Its mechanism involves modulating the immune response against specific allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ALK-depot SQ mites.